Here are five details:
1. Integer sold the product lines for $600 million in cash.
2. The company will use the proceeds to reduce debt by approximately $550 million. It will redeem outstanding 9.125 percent senior notes, repay the outstanding balance of its revolving credit facility and prepay outstanding term B loans.
3. After the divestiture, Integer will have $1.2 billion in revenue, higher margins, increased earnings, greater returns on invested capital and significantly lower debt leverage, according to Integer CEO Joe Dziedzic.
4. The company said lower interest from the debt reduction will offset the net income being divested and free cash flow won’t significantly change.
5. Details on the divestiture’s financial impact will be reported in 2018 second quarter financial results Aug. 2.
More articles on supply chain:
Integer to divest surgical, orthopedics product lines for $600M — 7 quick facts
Eyepoint expects to secure $25.5M to support 2 product launches — 5 insights
Johnson & Johnson’s DePuy Synthes launches self-shortening Dynacord suture — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.